Cerba Research was one of the first organizations in Europe to offer multispectral multiplex IHC services to pharmaceutical and biotechnology companies.

Cerba Research offers both custom multiplex development and validation, as well as panels that come already validated for specific indications.
Some examples are:
Our in-depth analytical validation ensures the quality of this robust protocol on solid tumor tissues.
Discover our poster presented at the AACR 2022 (American Association of Cancer Research)
Reach out to our experts and see how we can help advance your clinical trial in the field of Multiplex